Quantcast

Latest Cephalon Stories

2014-06-23 16:25:15

KANSAS CITY, Kan., June 23, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the appointment of former Cephalon, Inc., executive Robert P. Roche, Jr. to its Board of Directors. Mr. Roche has extensive operational and product launch expertise working for leading pharmaceutical...

2014-06-23 12:29:37

BOCA RATON, Fla., June 23, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has filed an ANDA with a Paragraph IV certification for bendamustine hydrochloride powder for IV (infusion), 25 mg/vial and 100 mg/vial, a generic version of Treanda® by Cephalon, Inc. On May 27, 2014, Cephalon, Inc. filed a Paragraph IV lawsuit against Breckenridge and its development and manufacturing partner Natco Pharma Limited in the United States District Court for the...

2014-05-30 16:25:02

DUBLIN, May 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil(® )(armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil(®) is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or...

2014-04-03 12:30:25

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management SummaryGBI Research has released the pharma report "Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management". The...

2014-02-04 20:22:43

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/f3g6bf/pain_management) has announced the addition of the "Concise Analysis on the International Pain Management Treatment Markets" [http://www.researchandmarkets.com/research/f3g6bf/pain_management ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Pain management describes a particular set of drugs, analgesics, which...

2014-02-04 08:34:45

DUBLIN, Feb. 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. Actavis' ANDA product is a generic version of Cephalon's Treanda(®), a treatment for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Cephalon, Inc. filed suit against Actavis on January 31,...

2014-01-27 08:28:11

SUNNYVALE, Calif., Jan. 27, 2014 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that Tom O'Neil has joined the company as Chief Financial Officer. Mr. O'Neil brings more than 15 years of industry experience to Sorbent. In this role, he will oversee Sorbent's financial operations, reporting directly to Detlef Albrecht, M.D., Sorbent's President and Chief Executive Officer. "Tom...

2014-01-22 12:27:21

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market TransformationSummaryGBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to...

2014-01-09 08:28:57

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran William Marth, as Chairman of the Board of Directors. Mr. Marth was the President and CEO of Teva - Americas until the end of 2012, and served as a senior advisor to Teva Pharmaceuticals until the end of 2013. During his tenure at Teva -...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.